Title |
Recent progress in sodium channel modulators for pain
|
---|---|
Published in |
Bioorganic & Medicinal Chemistry Letters, June 2014
|
DOI | 10.1016/j.bmcl.2014.06.038 |
Pubmed ID | |
Authors |
Sharan K. Bagal, Mark L. Chapman, Brian E. Marron, Rebecca Prime, R. Ian Storer, Nigel A. Swain |
Abstract |
Voltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins and Nav drug discovery is an exciting field. Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda®, Synchropatch® and Qube®. Moreover, emerging clinical data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful prospective Nav drug discovery. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | <1% |
Germany | 1 | <1% |
Switzerland | 1 | <1% |
India | 1 | <1% |
United Kingdom | 1 | <1% |
United States | 1 | <1% |
Unknown | 189 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 43 | 22% |
Student > Ph. D. Student | 28 | 14% |
Student > Master | 27 | 14% |
Student > Bachelor | 26 | 13% |
Other | 12 | 6% |
Other | 24 | 12% |
Unknown | 35 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 33 | 17% |
Chemistry | 31 | 16% |
Medicine and Dentistry | 27 | 14% |
Biochemistry, Genetics and Molecular Biology | 23 | 12% |
Neuroscience | 15 | 8% |
Other | 23 | 12% |
Unknown | 43 | 22% |